SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Hester Biosciences - Quaterly Results

09 May 2025 Evaluate
The March 2025 quarter revenue stood at Rs. 766.72 millions, up 5.21% as compared to Rs. 728.72 millions during the corresponding quarter last year.A comparatively good net profit growth of 29.66% to Rs. 96.35 millions was reported for the quarter ended March 2025 compared to Rs. 74.31 millions of previous same quarter.The company reported a good operating profit of 147.60 millions compared to 136.18 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 766.72 728.72 5.21 2864.66 2851.55 0.46 2864.66 2851.55 0.46
Other Income 10.58 12.03 -12.05 47.64 42.62 11.78 47.64 42.62 11.78
PBIDT 147.60 136.18 8.39 557.08 516.03 7.95 557.08 516.03 7.95
Interest 12.49 13.10 -4.66 53.67 50.93 5.38 53.67 50.93 5.38
PBDT 135.11 123.08 9.77 503.41 465.10 8.24 503.41 465.10 8.24
Depreciation 20.28 20.83 -2.64 85.81 97.78 -12.24 85.81 97.78 -12.24
PBT 114.83 102.25 12.30 417.60 367.32 13.69 417.60 367.32 13.69
TAX 18.48 27.94 -33.86 99.18 95.73 3.60 99.18 95.73 3.60
Deferred Tax -18.23 -4.82 278.22 -13.52 -0.62 2080.65 -13.52 -0.62 2080.65
PAT 96.35 74.31 29.66 318.42 271.59 17.24 318.42 271.59 17.24
Equity 85.07 85.07 0.00 85.07 85.07 0.00 85.07 85.07 0.00
PBIDTM(%) 19.25 18.69 3.01 19.45 18.10 7.46 19.45 18.10 7.46

Hester Biosciences Share Price

1492.80 20.80 (1.41%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×